Direxion Daily Biotech Top 5 Bull 2X ETF
TBXU
New York Stock Exchange Arca- -
USD
- -
- -
- -
- -
(- -)
Recent
price
- -
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Direxion Shares ETF Trust - Direxion Daily Biotech Top 5 Bull 2X ETF (TBXU) is a leveraged exchange-traded fund that seeks daily investment results, before fees and expenses, equal to 200% of the performance of the NYSE Biotechnology Top 5 Equal Weight Index. The fund, under normal circumstances, invests at least 80% of its net assets (plus any borrowings for investment purposes) in financial instruments including swaps, futures contracts, options, and exchange-traded funds that provide leveraged exposure to an equal-weighted basket of the top five U.S.-listed biotechnology companies by market capitalization; it also holds cash equivalents and money market instruments to collateralize derivatives. TBXU targets sophisticated traders and investors seeking amplified short-term returns from biotechnology sector leaders across therapeutic areas such as gene editing, precision medicine, and rare diseases, with operations focused on U.S. public equity markets. Launched on October 1, 2025, as part of Direxion's Titans suite of leveraged and inverse ETFs, TBXU represents a major strategic expansion into concentrated sector baskets, alongside companion products like Direxion Daily Biotech Top 5 Bear 2X ETF, Direxion Daily Technology Top 5 Bull 2X ETF (TTXU), Direxion Daily Semiconductors Top 5 Bull 2X ETF (TSXU), and Direxion Daily Energy Top 5 Bull 2X ETF (TEXU). This suite debuted in late September/early October 2025 to provide traders with 2X bull and bear exposure to top performers in high-growth industries amid market volatility. The Direxion Shares ETF Trust, established in 2006 and managed by Rafferty Asset Management, LLC, maintains its principal headquarters at 1301 Avenue of the Americas, New York, New York, with the broader Direxion brand tracing origins to 1997.